Metastasis directed Lu-177 PSMA Therapy in Prostate Cancer Patients with Oligometastatic Disease
Lutetium-177 labelled prostate-specific membrane antigen (177Lu-PSMA) is a promising new therapeutic approach to treat metastatic prostate cancer which has been approved recently by the FDA in the treatment of metastatic castration-resistant prostate cancer (mCRPC).